All articles tagged with #epinephrine
Jo Frost, known as Supernanny, revealed she has been diagnosed with a life-threatening condition called anaphylaxis, which causes severe allergic reactions to certain foods and requires immediate treatment with epinephrine. She shared her experience to raise awareness about the condition and its impact on daily life.
Maggie Habashy, a woman from Minnesota, suffers from exercise-induced anaphylaxis, a rare and potentially life-threatening allergy triggered by physical activity. Despite undergoing numerous tests, her condition remains unique as it is not linked to any food allergies, unlike most cases. Habashy must carry epinephrine at all times and be vigilant about her body's signals to prevent severe reactions. Her specialist, Dr. Micah Karasov, advises immediate cessation of exercise at the onset of symptoms to manage the condition effectively.
Maggie Habashy, a woman from Minnesota, suffers from exercise-induced anaphylaxis, a rare and potentially life-threatening allergy triggered by physical activity. Despite undergoing numerous tests, her condition remains unique as it is not linked to any food allergies, unlike most cases. Habashy must carry epinephrine at all times and be vigilant about her body's signals to prevent severe reactions. Her specialist, Dr. Micah Karasov, advises immediate cessation of exercise at the onset of symptoms to manage the condition effectively.
The FDA has rejected the approval of Neffy, an epinephrine nasal spray that would have been the first needle-free alternative to EpiPens. The agency has requested additional research to support approval, despite its advisory committee recommending the drug in May. Currently, all available epinephrine treatments require injection, posing a challenge for those afraid of needles. Concerns were raised about the lack of clinical data, particularly in patients experiencing anaphylaxis. The drugmaker plans to appeal the FDA's request and resubmit its application in 2024.
A committee of the FDA's outside advisers has voted in favor of ARS Pharmaceuticals' proposed epinephrine nasal spray, Neffy, which could soon be the first needle-free option for treating severe allergic reactions. The spray is designed to deliver a 2 milligram dose of epinephrine, which can reverse the symptoms of a life-threatening allergic reaction. The FDA is expected to issue its final verdict on whether to approve Neffy in mid-2023. If approved, the company hopes to launch the prescription spray by the end of the year.